Danazol for paroxysmal nocturnal hemoglobinuria

William J. Harrington, Luciano Kolodny, Lawrence L. Horstman, Wenche Jy, Yeon Ahn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patients refractory to glucocorticoids and requiring blood transfusions, an alternative therapy is needed. We studied danazol therapy in 5 patients refractory to other treatments. Four of the 5 benefited, showing rise in hematocrit and eventual cessation of transfusion requirements. Remissions lasted ≤2 years in 3 and 10 years in 1 patient. Danazol was well-tolerated without serious side effects. Danazol appears to be a good alternative treatment in PNH.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalAmerican Journal of Hematology
Volume54
Issue number2
DOIs
StatePublished - Feb 26 1997

Fingerprint

Danazol
Paroxysmal Hemoglobinuria
Glucocorticoids
Pancytopenia
Therapeutics
Complementary Therapies
Hemolysis
Hematocrit
Blood Transfusion
Blood Cells
Membrane Proteins
Stem Cells
Wounds and Injuries

Keywords

  • androgen therapy
  • danazol
  • PNH

ASJC Scopus subject areas

  • Hematology

Cite this

Danazol for paroxysmal nocturnal hemoglobinuria. / Harrington, William J.; Kolodny, Luciano; Horstman, Lawrence L.; Jy, Wenche; Ahn, Yeon.

In: American Journal of Hematology, Vol. 54, No. 2, 26.02.1997, p. 149-154.

Research output: Contribution to journalArticle

Harrington, William J. ; Kolodny, Luciano ; Horstman, Lawrence L. ; Jy, Wenche ; Ahn, Yeon. / Danazol for paroxysmal nocturnal hemoglobinuria. In: American Journal of Hematology. 1997 ; Vol. 54, No. 2. pp. 149-154.
@article{5dabd14ffae644439c86489392462386,
title = "Danazol for paroxysmal nocturnal hemoglobinuria",
abstract = "Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patients refractory to glucocorticoids and requiring blood transfusions, an alternative therapy is needed. We studied danazol therapy in 5 patients refractory to other treatments. Four of the 5 benefited, showing rise in hematocrit and eventual cessation of transfusion requirements. Remissions lasted ≤2 years in 3 and 10 years in 1 patient. Danazol was well-tolerated without serious side effects. Danazol appears to be a good alternative treatment in PNH.",
keywords = "androgen therapy, danazol, PNH",
author = "Harrington, {William J.} and Luciano Kolodny and Horstman, {Lawrence L.} and Wenche Jy and Yeon Ahn",
year = "1997",
month = "2",
day = "26",
doi = "10.1002/(SICI)1096-8652(199702)54:2<149::AID-AJH9>3.0.CO;2-X",
language = "English",
volume = "54",
pages = "149--154",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Danazol for paroxysmal nocturnal hemoglobinuria

AU - Harrington, William J.

AU - Kolodny, Luciano

AU - Horstman, Lawrence L.

AU - Jy, Wenche

AU - Ahn, Yeon

PY - 1997/2/26

Y1 - 1997/2/26

N2 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patients refractory to glucocorticoids and requiring blood transfusions, an alternative therapy is needed. We studied danazol therapy in 5 patients refractory to other treatments. Four of the 5 benefited, showing rise in hematocrit and eventual cessation of transfusion requirements. Remissions lasted ≤2 years in 3 and 10 years in 1 patient. Danazol was well-tolerated without serious side effects. Danazol appears to be a good alternative treatment in PNH.

AB - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patients refractory to glucocorticoids and requiring blood transfusions, an alternative therapy is needed. We studied danazol therapy in 5 patients refractory to other treatments. Four of the 5 benefited, showing rise in hematocrit and eventual cessation of transfusion requirements. Remissions lasted ≤2 years in 3 and 10 years in 1 patient. Danazol was well-tolerated without serious side effects. Danazol appears to be a good alternative treatment in PNH.

KW - androgen therapy

KW - danazol

KW - PNH

UR - http://www.scopus.com/inward/record.url?scp=1842368532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842368532&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(199702)54:2<149::AID-AJH9>3.0.CO;2-X

DO - 10.1002/(SICI)1096-8652(199702)54:2<149::AID-AJH9>3.0.CO;2-X

M3 - Article

VL - 54

SP - 149

EP - 154

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -